90 related articles for article (PubMed ID: 32644027)
1. Tocilizumab for COVID-19: a real 'miracle drug'?
Nasim S; Hashmi SH; Azim D; Kumar S; Nasim J
Infect Dis (Lond); 2020 Sep; 52(9):681-682. PubMed ID: 32644027
[No Abstract] [Full Text] [Related]
2. Tocilizumab in COVID-19: Beware the risk of intestinal perforation.
Vikse J; Henry BM
Int J Antimicrob Agents; 2020 Jul; 56(1):106009. PubMed ID: 32389721
[No Abstract] [Full Text] [Related]
3. Anti-IL6R role in treatment of COVID-19-related ARDS.
Buonaguro FM; Puzanov I; Ascierto PA
J Transl Med; 2020 Apr; 18(1):165. PubMed ID: 32290847
[No Abstract] [Full Text] [Related]
4. Dramatic improvement after tocilizumab of severe COVID-19 in a child with sickle cell disease and acute chest syndrome.
Odièvre MH; de Marcellus C; Ducou Le Pointe H; Allali S; Romain AS; Youn J; Taytard J; Nathan N; Corvol H
Am J Hematol; 2020 Aug; 95(8):E192-E194. PubMed ID: 32358817
[No Abstract] [Full Text] [Related]
5. First, Do No Harm: Caution Against Use of Tocilizumab in COVID-19.
Mastroianni F
Chest; 2020 Nov; 158(5):2233. PubMed ID: 33160536
[No Abstract] [Full Text] [Related]
6. Interleukin 6 levels after tocilizumab administration in transplant recipients with COVID-19.
Gade AR; Alavala H; Allam SR
Kidney Int; 2020 Oct; 98(4):1054. PubMed ID: 32650019
[No Abstract] [Full Text] [Related]
7. Early tocilizumab treatment could improve survival among COVID-19 patients.
Campins L; Boixeda R; Perez-Cordon L; Aranega R; Lopera C; Force L
Clin Exp Rheumatol; 2020; 38(3):578. PubMed ID: 32456769
[No Abstract] [Full Text] [Related]
8. Tocilizumab for Hemophagocytic Syndrome in a Kidney Transplant Recipient With COVID-19.
Faguer S; Del Bello A; Abravanel F; Nicolau-Travers ML; Kamar N
Ann Intern Med; 2020 Sep; 173(6):501-503. PubMed ID: 32432518
[No Abstract] [Full Text] [Related]
9. COVID-19 in a patient with systemic sclerosis treated with tocilizumab for SSc-ILD.
Mihai C; Dobrota R; Schröder M; Garaiman A; Jordan S; Becker MO; Maurer B; Distler O
Ann Rheum Dis; 2020 May; 79(5):668-669. PubMed ID: 32241792
[No Abstract] [Full Text] [Related]
10. Interleukin-6 receptor antagonist therapy to treat SARS-CoV-2 driven inflammatory syndrome in a kidney transplant recipient.
Allam SR; Dao A; Madhrira MM; Antiporta PB; Nair RR; Guiteau JJ; Reyad AI
Transpl Infect Dis; 2020 Aug; 22(4):e13326. PubMed ID: 32406985
[No Abstract] [Full Text] [Related]
11. Interleukin 6-blockade treatment for severe COVID-19 in two patients with multiple myeloma.
Chaidos A; Katsarou A; Mustafa C; Milojkovic D; Karadimitris A
Br J Haematol; 2020 Jul; 190(1):e9-e11. PubMed ID: 32369612
[No Abstract] [Full Text] [Related]
12. COVID-19: associated morbidity and mitigation strategies.
Mahmood SN; Woods CJ; Chan CM
Infect Dis (Lond); 2020; 52(12):923-926. PubMed ID: 32726166
[No Abstract] [Full Text] [Related]
13. Viral aetiology and clinical characteristics of acute respiratory tract infections in Shenzhen during epidemic of coronavirus disease 2019.
Zhang D; Jiang Y; Hua J; Liu Q; Wen W; Zhu M; Du J; Liu H
Infect Dis (Lond); 2020 Aug; 52(8):590-592. PubMed ID: 32452728
[No Abstract] [Full Text] [Related]
14. New therapeutic opportunities for COVID-19 patients with Tocilizumab: Possible correlation of interleukin-6 receptor inhibitors with osteonecrosis of the jaws.
Bennardo F; Buffone C; Giudice A
Oral Oncol; 2020 Jul; 106():104659. PubMed ID: 32209313
[No Abstract] [Full Text] [Related]
15. The complement inhibitors in COVID-19: future expectations.
Korotchaeva Y; Kozlovskaya N; Bobrova L; Kamyshova E; Demyanova K; Moiseev S
Eur Rev Med Pharmacol Sci; 2020 Jun; 24(12):6480-6481. PubMed ID: 32633332
[No Abstract] [Full Text] [Related]
16. Patient-Driven Discontinuation of Dupilumab During the COVID-19 Pandemic in Two Academic Hospital Clinics at the University of Toronto.
Georgakopoulos JR; Yeung J
J Cutan Med Surg; 2020; 24(4):422-423. PubMed ID: 32434413
[No Abstract] [Full Text] [Related]
17. Increased CD4/CD8 ratio as a risk factor for critical illness in coronavirus disease 2019 (COVID-19): a retrospective multicentre study.
Pallotto C; Suardi LR; Esperti S; Tarquini R; Grifoni E; Meini S; Valoriani A; Di Martino S; Cei F; Sisti E; Piani F; Botta A; Salomoni E; Baragli F; Blanc P
Infect Dis (Lond); 2020 Sep; 52(9):675-677. PubMed ID: 32543971
[No Abstract] [Full Text] [Related]
18. Laboratory abnormalities related to prolonged hospitalization in COVID-19.
Tezcan ME; Doğan Gökçe G; Ozer RS
Infect Dis (Lond); 2020 Sep; 52(9):666-668. PubMed ID: 32543300
[No Abstract] [Full Text] [Related]
19. A familial cluster of severe coronavirus disease 2019 that required intubation of all family members.
Katsuno T; Suzuki M; Ishikane M; Kinoshita N; Tsukada A; Morita C; Kusaba Y; Sakamoto K; Yamaguchi Y; Tsujimoto Y; Hashimoto M; Terada J; Takasaki J; Izumi S; Okuhama A; Ide S; Moriyama Y; Matsuda K; Takamatsu Y; Mitsuya H; Hojo M; Sugiyama H
Infect Dis (Lond); 2020 Oct; 52(10):755-758. PubMed ID: 32615051
[No Abstract] [Full Text] [Related]
20. Cytokine Storm Drugs Move from CAR T to COVID-19.
Cancer Discov; 2020 Jul; 10(7):OF8. PubMed ID: 32371479
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
